Answers are grounded in this paper and cite their sources.
Real-world evidence study shows monoclonal treatment raises ARIA risk while reducing inpatient visits, suggesting important implications for personalized care.
Monoclonal treatment was associated with higher cumulative hazard of ARIA but fewer inpatient visits. This study indicated the potential of RWE, despite its distinct observational design and differences from randomized clinical trials, to serve as a credible proof-of-concept in postapproval assessment and to inform personalized treatment guidelines based on patients' risk factors.
No takes yet. Share an insight, caveat, or question.
Dangpiaei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: